Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
Key Takeaways Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.The companies plan to provide further details about the research at a scientific forum in 2025.
Teva, Sanofi say bowel disease drug met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
Teva, Sanofi Say IBD Treatment Achieved Higher Remission at Trial
Teva Pharmaceuticals and Sanofi report that the latest trial of their jointly developed treatment for inflammatory bowel disease met its primary endpoints. The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group.
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.
Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals. Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD),
Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
US affiliate and partner Sanofi (SNY) said Tuesday that a phase 2b study of Teva's investigational duvakitug drug to treat ulcerative colitis and Crohn's disease met its primary endpoints. Ulcerative colitis and Crohn's disease are the most common types of inflammatory bowel disease.
Medical Xpress on MSN1d
Electrical stimulation of ears shows promise for treating ulcerative colitis
A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...
The Lancet6h
Guselkumab in the IL-23 inhibition landscape for ulcerative colitis
The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum with a relapsing–remitting course, has been a long and challenging journey, ...
Medindia3d
Beta Ionone: A New Hope for Ulcerative Colitis Patients
Discover how β-ionone offers relief from ulcerative colitis by enhancing gut health, reducing inflammation, and restoring ...
A Game Plan for Your Moderate-to-Severe Ulcerative Colitis
The symptoms of UC are unpredictable. On a given day it can cause an urge to use the bathroom repeatedly, or blood in your ...
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
Teva and Sanofi's Phase 2b RELIEVE UCCD study shows duvakitug improves remission in ulcerative colitis and response in ...
clinicaladvisor.com6d
Ulcerative Colitis Statistics
Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment.
UM study shows electrical stimulation as promising treatment for ulcerative colitis
A new research study conducted in Manitoba has shown that electrical stimulation of the ears has shown promise as a possible treatment for ulcerative colitis.
Irish Independent on MSN5d
Crohn’s and colitis are not fun at Christmas, but new cookbook offers gut-friendly recipes to avoid flare-ups
At Christmas people with Crohn’s disease and ­colitis can often be left at risk of a digestive flare-up as they are tempted ...
J&J submits sBLA for pediatric indication for Simponi in ulcerative colitis
Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application to the U.S. FDA to add an additional ...